SCHEMBL5535309

SCHEMBL5535309

CCCCCCOC(=O)N1CCC[N]CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.50
POLB P06746 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
NAAA Q02083 1/20 0.41
PLA2G2A P14555 2/20 0.40
GBA2 Q9HCG7 1/20 0.40
L3MBTL1 Q9Y468 3/20 0.39
EPHX1 P07099 1/20 0.39
HRH2 P25021 1/20 0.39
HRH1 P35367 1/20 0.39
TSHR P16473 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542964 0.98 SMN1; SMN2 (0.51) LMNAPOLBSMN1; SMN2NAAAPLA2G2A
SCHEMBL4687715 0.94 LMNA (0.55) LMNAPOLBSMN1; SMN2NAAAPLA2G2A
SCHEMBL7510677 0.92 POLB (0.57) LMNAPOLBSMN1; SMN2NAAAPLA2G2A
SCHEMBL5543852 0.88 SMN1; SMN2 (0.44) LMNAPOLBSMN1; SMN2L3MBTL1TSHR
SCHEMBL1937433 0.88 POLB (0.63) LMNAPOLBSMN1; SMN2PLA2G2AHRH2
SCHEMBL5935756 0.86 LMNA (0.60) LMNAPOLBSMN1; SMN2NAAAGBA2
SCHEMBL19830587 0.86 LMNA (0.60) LMNAPOLBSMN1; SMN2NAAAGBA2
SCHEMBL5935769 0.84 LMNA (0.58) LMNAPOLBSMN1; SMN2NAAAGBA2
SCHEMBL5405182 0.84 SMN1; SMN2 (0.62) LMNAPOLBSMN1; SMN2NAAAGBA2
SCHEMBL10700528 0.82 SMN1; SMN2 (0.60) LMNAPOLBSMN1; SMN2NAAAGBA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 LMNA 4152/4885POLB 1637/4885SMN1; SMN2 3985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.